<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636996</url>
  </required_header>
  <id_info>
    <org_study_id>CIFuwaiHospital2019-1220</org_study_id>
    <nct_id>NCT04636996</nct_id>
  </id_info>
  <brief_title>Effects of AI Assisted Follow-up Strategy on Secondary Prevention in CABG Patients</brief_title>
  <official_title>Effects of Artificial Intelligence Assisted Follow-up Strategy Based on a New Remote Contactless Sleep Monitoring System on Secondary Prevention in Patients Received Coronary Artery Bypass Grafting Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is trying to find out whether artificial intelligence assisted follow-up&#xD;
      strategy will improve secondary prevention in CABG patients. In addition, we will test&#xD;
      whether rural patients may have more benefits under the new follow-up strategy based on the&#xD;
      artificial intelligence device compared with urban patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a large population of coronary heart disease patients in China, which needs more&#xD;
      attention to optimize the secondary prevention and improve the prognosis. Secondary&#xD;
      prevention has been showing the effects of improving symptoms, preventing disease&#xD;
      progression, improving prognosis, and reducing mortality in patients received coronary artery&#xD;
      bypass grafting (CABG) surgery. In this study, we are trying to evaluate the effectiveness of&#xD;
      artificial intelligence (AI) assisted follow-up strategy on secondary prevention for patients&#xD;
      received CABG surgery. And we are trying to find out whether there is difference in secondary&#xD;
      prevention of coronary heart disease between urban and rural patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart rate</measure>
    <time_frame>35 days</time_frame>
    <description>The average heart rate during the first 35 days postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of different sleep stages</measure>
    <time_frame>35 days</time_frame>
    <description>It includes duration of falling asleep, light sleep, and deep sleep period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pulse oxygen saturation</measure>
    <time_frame>35 days</time_frame>
    <description>The average pulse oxygen saturation during the sleep will be evaluated by the sleep monitor device automatically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum pulse oxygen saturation</measure>
    <time_frame>35 days</time_frame>
    <description>The pulse oxygen saturation during the sleep will be recorded by the sleep monitor device and the minimum pulse oxygen saturation will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>35 days</time_frame>
    <description>It will be evaluated with the visual analogue scale from 0 to 10. Zero is the lowest level of pain and 10 is the highest level of pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>35 days</time_frame>
    <description>It will be evaluated with Morisky Medication Adherence Scale (MMAS-4). The patients will receive four questions, which are answered by Yes or No ((Yes=0 and No=1) through the scoring system. Zero is the lowest level of medication adherence and 4 is the highest level of medication adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission rate</measure>
    <time_frame>35 days</time_frame>
    <description>It is defined as re-admission between discharge to 35 days after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>35 days</time_frame>
    <description>refers to the incidence of death from the day of surgery to the end of the trial, regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of medical expenses</measure>
    <time_frame>35 days</time_frame>
    <description>It refers to the total medical expenses for CABG surgery and the following follow-up process.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Artificial Intelligence</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>artificial intelligence assisted follow-up group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>artificial intelligence assisted follow-up group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>artificial intelligence assisted follow-up</intervention_name>
    <description>We will use a new portable artificial intelligence assisted device to monitor the patients' postoperative heart rate and sleep quality, guiding the following follow-up process</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>artificial intelligence assisted follow-up group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18-70, male or female&#xD;
&#xD;
          2. Received isolated CABG procedure due to coronary artery disease&#xD;
&#xD;
          3. Having a smartphone and are willing to cooperate&#xD;
&#xD;
          4. Signing written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing CABG + valve replacement surgery&#xD;
&#xD;
          2. Postoperative hospital stays more than 10 days (Due to limited postoperative follow-up&#xD;
             time and unstable condition such as incision infection, angina, etc.)&#xD;
&#xD;
          3. Patients with lung, liver, and kidney failure (Due to organ dysfunction which needs&#xD;
             more professional health care and not suitable for this trial)&#xD;
&#xD;
          4. Patients with Urinary system diseases (Getting up during sleep, which will interfere&#xD;
             with sleep monitoring)&#xD;
&#xD;
          5. Patients mentally or legally disabled&#xD;
&#xD;
          6. Breastfeeding or pregnant women&#xD;
&#xD;
          7. End-stage disease, estimated survival time is less than 3 months&#xD;
&#xD;
          8. Participate in other perioperative intervention studies at the same time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Shi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Center for Cardiovascular Disease, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia Shi, MD</last_name>
    <phone>86-10-88322467</phone>
    <email>shiandypumc@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Shen C, Ge J. Epidemic of Cardiovascular Disease in China: Current Perspective and Prospects for the Future. Circulation. 2018 Jul 24;138(4):342-344. doi: 10.1161/CIRCULATIONAHA.118.033484.</citation>
    <PMID>30571361</PMID>
  </results_reference>
  <results_reference>
    <citation>Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 6;385(9984):2264-2271. doi: 10.1016/S0140-6736(14)61730-X. Epub 2015 Mar 4.</citation>
    <PMID>25748612</PMID>
  </results_reference>
  <results_reference>
    <citation>Høgh AL. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness. Dan Med J. 2012 Sep;59(9):B4514. Review.</citation>
    <PMID>22951205</PMID>
  </results_reference>
  <results_reference>
    <citation>Kulik A. Secondary prevention after coronary artery bypass graft surgery: a primer. Curr Opin Cardiol. 2016 Nov;31(6):635-643. Review.</citation>
    <PMID>27583372</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011 Nov 29;124(22):2458-73. doi: 10.1161/CIR.0b013e318235eb4d. Epub 2011 Nov 3. Erratum in: Circulation. 2015 Apr 14;131(15):e408.</citation>
    <PMID>22052934</PMID>
  </results_reference>
  <results_reference>
    <citation>Dorje T, Zhao G, Scheer A, Tsokey L, Wang J, Chen Y, Tso K, Tan BK, Ge J, Maiorana A. SMARTphone and social media-based Cardiac Rehabilitation and Secondary Prevention (SMART-CR/SP) for patients with coronary heart disease in China: a randomised controlled trial protocol. BMJ Open. 2018 Jun 30;8(6):e021908. doi: 10.1136/bmjopen-2018-021908.</citation>
    <PMID>29961032</PMID>
  </results_reference>
  <results_reference>
    <citation>Pradeepa R, Rajalakshmi R, Mohan V. Use of Telemedicine Technologies in Diabetes Prevention and Control in Resource-Constrained Settings: Lessons Learned from Emerging Economies. Diabetes Technol Ther. 2019 Jun;21(S2):S29-S216. doi: 10.1089/dia.2019.0038. Review.</citation>
    <PMID>31169429</PMID>
  </results_reference>
  <results_reference>
    <citation>Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. Review.</citation>
    <PMID>22588748</PMID>
  </results_reference>
  <results_reference>
    <citation>Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008 May;29(10):1327-34. doi: 10.1093/eurheartj/ehn123. Epub 2008 Mar 29.</citation>
    <PMID>18375982</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu ZK, Vikman S, Laurikka J, Pehkonen E, Iivainen T, Huikuri HV, Tarkka MR. Nonlinear heart rate variability in CABG patients and the preconditioning effect. Eur J Cardiothorac Surg. 2005 Jul;28(1):109-13. Epub 2005 Apr 8.</citation>
    <PMID>15982594</PMID>
  </results_reference>
  <results_reference>
    <citation>Lakusic N, Mahovic D, Sonicki Z, Slivnjak V, Baborski F. Outcome of patients with normal and decreased heart rate variability after coronary artery bypass grafting surgery. Int J Cardiol. 2013 Jun 20;166(2):516-8. doi: 10.1016/j.ijcard.2012.04.040. Epub 2012 May 5.</citation>
    <PMID>22560918</PMID>
  </results_reference>
  <results_reference>
    <citation>Cox JL, Bata IR, Gregor RD, Johnstone DE, Wolf HK. Trends in event rate and case fatality of patients hospitalized with myocardial infarction between 1984 and 2001. Can J Physiol Pharmacol. 2006 Jan;84(1):121-7.</citation>
    <PMID>16845896</PMID>
  </results_reference>
  <results_reference>
    <citation>Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld A, Gard A, Jernberg T. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. Circulation. 2017 Apr 18;135(16):1481-1489. doi: 10.1161/CIRCULATIONAHA.116.026336. Epub 2017 Feb 8.</citation>
    <PMID>28179398</PMID>
  </results_reference>
  <results_reference>
    <citation>Roberts DM, Zimmer WE, Watterson DM. The use of synthetic oligodeoxyribonucleotides in the examination of calmodulin gene and protein structure and function. Methods Enzymol. 1987;139:290-303.</citation>
    <PMID>3035326</PMID>
  </results_reference>
  <results_reference>
    <citation>McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS; SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016 Sep 8;375(10):919-31. doi: 10.1056/NEJMoa1606599. Epub 2016 Aug 28.</citation>
    <PMID>27571048</PMID>
  </results_reference>
  <results_reference>
    <citation>Otto-Yáñez M, Torres-Castro R, Nieto-Pino J, Mayos M. [Obstructive sleep apnea-hypopnea and stroke]. Medicina (B Aires). 2018;78(6):427-435. Review. Spanish.</citation>
    <PMID>30504110</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 14, 2020</last_update_submitted>
  <last_update_submitted_qc>November 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Deputy director of the anesthesia center</investigator_title>
  </responsible_party>
  <keyword>artificial intelligence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

